Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekten av Glp-1 och antidiabetiska sgLT2-agenter vid myokardieinfarkt och ultrakänslig inflammatorisk övervakning (GALACTUS-studien) (GALACTUS)

2 november 2026 uppdaterad av: Hilda Elizabeth Macías Cervantes, Instituto Mexicano del Seguro Social

GLP-1 och antidiabetiska SGLT2-agenter för hjärtinfarkt och ultrakänslig inflammatorisk övervakning: En öppen pilotstudie

The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.

During acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg/L after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP > 2.0 mg/L) continues for a year.

Aside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, double-blind, multicenter trial. This trial compared five days of oral colchicine with a placebo and found no difference in infarct size between the groups at five days or three months, as measured by cardiac magnetic resonance imaging.

SGLT-2 inhibitors are drugs that have revolutionized the management of cardiovascular diseases, offering proven benefits for patients with heart failure and notable nephroprotective effects. However, their use after acute myocardial infarction has not yet been sufficiently established, as the only two published clinical trials so far failed to meet their primary goal of reducing hospitalizations for heart failure. Additionally, evidence of their use in post-AMI inflammation exists only in experimental studies. In experimental studies, SGLT2 global-knockout (KO) mice were used to demonstrate that dapagliflozin significantly influences cardiac fibrosis and inflammation, and markedly alters the gene expression profiles of macrophages and fibroblasts. Moreover, dapagliflozin directly inhibited macrophage-mediated inflammation, thereby suppressing cardiac fibroblast activation.

Similarly, only experimental studies have shown that semaglutide decreases elevated levels of TNF-α, IL-6, ROS, and MDA in the serum and cardiac tissues of obese mice. By lowering the expression of Cxcl2, S100a8, and S100a9 in neutrophils, semaglutide may help reduce cardiac inflammation and oxidative stress.

Therefore, the objective of this study is to compare the effects of dapagliflozin and semaglutide on inflammatory markers (hs-CRP and IL-6) in patients with acute ST-segment elevation myocardial infarction.

Studieöversikt

Detaljerad beskrivning

This is a small open-label pilot clinical trial to assess the effectiveness of dapagliflozin and semaglutide on inflammatory markers (IL-6 and hs-CRP) in patients with STEMI over 24 weeks. It will include patients over 18 years old with STEMI, with or without a diagnosis of type 2 diabetes, clinical obesity, and an initial serum hs-CRP level greater than 2.0 mg/L.

Inflammation markers will be measured upon patient admission after percutaneous coronary intervention and again after 24 weeks of treatment with the drugs. Patients will be discharged in accordance with STEMI treatment guidelines, and their medication adherence and tolerability will be monitored.

Studietyp

Interventionell

Inskrivning (Faktisk)

44

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Guanajuato
      • León, Guanajuato, Mexiko, 37320
        • Hospital de Especialidades No.1, Centro Médico Nacional del Bajío

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation.
  • Diagnosed with type 2 diabetes.
  • Initial serum high-sensitivity CRP value > 2.0 mg/L.
  • Clinically obese.
  • LVEF >50%.

Exclusion Criteria:

  • Patients who have recently received immunosuppressive therapy
  • Patients with a history of ischemic heart disease
  • Known allergy to any of the medications used
  • Use of any of the study drugs more than 6 months prior to randomization
  • Patients experiencing diabetic ketoacidosis
  • Patients with hemodynamic instability (mean arterial pressure <60 mmHg while on vasopressors)
  • Pregnant women
  • Patients with a history or current diagnosis of cancer
  • Patients with documented active infections, such as pneumonia or urinary tract infections
  • Patients with pancreatitis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dapagliflozin

Dapagliflozin 10 mg daily for 24 weeks

10 mg dapagliflozin daily for 24 weeks

Aktiv komparator: Semaglutide

Semaglutide 3 mg, gradually increasing to 14 mg every 24 hours over 24 weeks.

Semaglutide 3 mg, gradually increasing to 14 mg every 24 hours over 24 weeks.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Inflammatory markers (high-sensitivity PCR)
Tidsram: 24 weeks.

Patients with hsCRP > 2 mg/L will be included, and a control will be taken to assess the change after 24 weeks of treatment.

24 weeks.
Inflammatory markers (interleukin 6)
Tidsram: 24 weeks

Patients with IL-6 > 2 ng/L will be included, and a control will be taken to assess the change after 24 weeks of treatment.

24 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Epicardial fat
Tidsram: 24 weeks

Epicardial fat will be assessed using non-invasive coronary tomography during hospitalization for STEMI and again after 24 weeks of treatment.

24 weeks
LDL cholesterol
Tidsram: 24 weeks

The impact of both interventions on LDL levels will be assessed after 24 weeks of treatment.

24 weeks
Change in glucose and HbA1c
Tidsram: 24 weeks

The effect of both interventions on fasting glucose and HbA1c levels will be assessed after 24 weeks of treatment.

24 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Rodolfo Guardado-Mendoza, Ph.D., Universidad de Guanajuato

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 december 2025

Primärt slutförande (Faktisk)

30 oktober 2026

Avslutad studie (Faktisk)

30 oktober 2026

Studieregistreringsdatum

Först inskickad

8 december 2025

Först inskickad som uppfyllde QC-kriterierna

8 december 2025

Första postat (Faktisk)

19 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 december 2025

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera